Membranous nephropathy in rheumatoid arthritis: a case report.
Rheumatoid arthritis is a chronic disease characterized by inflammation, abnormal cellular and humoral immune responses, synovial hyperplasia and rarely by renal involvement, characterized principally by secondary amyloidosis and nephrotoxic effects related to drugs, while renal lesions directly due to the disease itself are infrequent. In this report we describe a patient with rheumatoid arthritis who developed membranous nephropathy associated with nephrotic syndrome while receiving adalimumab, an anti-tumour necrosis factor-alpha drug.
Maruotti
N
N
Department of Rheumatology, University of Foggia Medical School, Italy.
Corrado
A
A
Gaudio
A
A
Cantatore
F P
FP
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D005260:Female; D015433:Glomerulonephritis, Membranous / Q000209:etiology* / Q000473:pathology*; D006801:Humans; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000209:etiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab